secwatch / observer
8-K filed May 24, 2023, 7:59 PM ET ticker ARQT CIK 0001787306
leadership confidence high sentiment neutral materiality 0.60

Arcutis CCO Ken Lock resigns; Ayisha Jeter named interim CCO

Arcutis Biotherapeutics, Inc.

item 5.02item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Ayisha Jeter

Interim Chief Commercial Officer
ARQT · Arcutis Biotherapeutics, Inc.
Filed
May 24, 2023, 7:59 PM ET
The Company has commenced a search for a permanent chief commercial officer and has appointed Ayisha Jeter, who has served as the Company’s Vice President of Market Access since joining the Company in June 2020, as interim chief commercial officer during the transition period.
Departed (interim)

Kenneth Lock

Senior Vice President and Chief Commercial Officer
ARQT · Arcutis Biotherapeutics, Inc.
Effective
2023-06-02
Successor
Ayisha Jeter
Filed
May 24, 2023, 7:59 PM ET
On May 22, 2023, Kenneth Lock notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as Senior Vice President and Chief Commercial Officer of the Company, effective as of June 2, 2023, to attend to personal matters.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ayisha Jeter was appointed as Interim Chief Commercial Officer at Arcutis Biotherapeutics, Inc..

Action
appointed
Role
Interim Chief Commercial Officer
Exact text from the filing
The Company has commenced a search for a permanent chief commercial officer and has appointed Ayisha Jeter, who has served as the Company’s Vice President of Market Access since joining the Company in June 2020, as interim chief commercial officer during the transition period.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Kenneth Lock resigned as Senior Vice President and Chief Commercial Officer at Arcutis Biotherapeutics, Inc..

Action
resigned
Role
Senior Vice President and Chief Commercial Officer
Exact text from the filing
On May 22, 2023, Kenneth Lock notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as Senior Vice President and Chief Commercial Officer of the Company, effective as of June 2, 2023, to attend to personal matters.
View on SEC.gov

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001787306-23-000048
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.